IBBQ - ETF AI Analysis
Top Page
Invesco Nasdaq Biotechnology ETF (IBBQ)
Rating:65Neutral
Price Target:―
Positive Factors
Low Expense Ratio
The fund charges relatively low fees for a specialized biotech ETF, which helps investors keep more of their returns over time.
Solid Recent Performance
The ETF has shown positive performance so far this year and over the past month, indicating recent strength in its holdings.
Established Large-Cap Biotech Core
Several of the largest positions are well-known, mature biotech companies that have delivered generally steady or strong results, providing a more stable core within a volatile sector.
Negative Factors
Heavy Sector Concentration
Almost all of the fund is invested in health care and biotechnology, which increases risk if this single sector faces a downturn.
Mixed Performance Among Top Holdings
A number of the larger positions have shown weak or negative performance this year, which can drag on the fund’s overall returns.
Limited Geographic Diversification
The ETF is almost entirely invested in U.S. companies, offering little protection if the U.S. market or regulatory environment for biotech weakens.
IBBQ vs. SPDR S&P 500 ETF (SPY)
AUM65.88M
RegionNorth America
Expense Ratio0.19%
Beta0.82
IssuerInvesco
Inception DateJun 11, 2021
Dividend Yield0.87%
Asset ClassEquity
Index TrackedNASDAQ / Biotechnology
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume17,852
30 Day Avg. Volume22,898
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
40.45Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering256
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBBQ Summary
The Invesco Nasdaq Biotechnology ETF (IBBQ) is a fund that follows the Nasdaq Biotechnology Index, focusing on U.S. biotech and drug companies within the health care sector. It holds many firms working on new medicines and treatments, including well-known names like Amgen and Gilead Sciences. Investors might consider IBBQ if they want growth potential from medical breakthroughs and a way to spread their bet across many biotech companies instead of picking single stocks. However, this ETF is heavily focused on biotech, so its price can swing a lot and may rise or fall quickly with news about drug trials and regulations.
How much will it cost me?The Invesco Nasdaq Biotechnology ETF (IBBQ) has an expense ratio of 0.19%, meaning you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it tracks an index rather than requiring frequent adjustments by fund managers.
What would affect this ETF?The Invesco Nasdaq Biotechnology ETF (IBBQ) could benefit from advancements in biotechnology and pharmaceutical innovation, as well as increased global demand for cutting-edge healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, or broader economic downturns that could impact funding for biotech firms. Its focus on U.S.-based companies and heavy exposure to the healthcare sector means it is particularly sensitive to changes in government healthcare policies and drug approval processes.
IBBQ Top 10 Holdings
IBBQ is very much a U.S. biotech story, with big drugmakers like Gilead and Amgen acting as the fund’s steady anchors—recently softer, but still broadly supportive. Vertex and Regeneron, once key growth engines, have been losing a bit of steam, which has weighed on overall momentum. On the brighter side, smaller names like Revolution Medicines and United Therapeutics are rising and adding some spark, while Biogen is quietly helping in the background. With almost everything tied to health care, the fund lives and dies by biotech sentiment rather than broad market trends.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Amgen | 7.26% | $4.79M | $185.95B | 20.17% | 77 Outperform | |
| Gilead Sciences | 7.11% | $4.69M | $161.86B | 20.13% | 78 Outperform | |
| Vertex Pharmaceuticals | 7.10% | $4.69M | $109.45B | -14.20% | 78 Outperform | |
| Regeneron | 6.23% | $4.11M | $79.44B | 21.87% | 78 Outperform | |
| Alnylam Pharma | 3.29% | $2.17M | $40.77B | 21.06% | 60 Neutral | |
| Insmed | 2.36% | $1.56M | $29.18B | 94.65% | 43 Neutral | |
| Biogen | 2.13% | $1.41M | $27.06B | 51.67% | 74 Outperform | |
| Revolution Medicines | 2.10% | $1.39M | $28.24B | 217.51% | 52 Neutral | |
| United Therapeutics | 2.00% | $1.32M | $24.86B | 90.88% | 79 Outperform | |
| Argenx Se | 1.79% | $1.18M | $48.29B | 26.21% | 79 Outperform |
IBBQ Technical Analysis
Negative
―
Price Trends
29.16
Negative
29.05
Negative
26.90
Positive
Market Momentum
>-0.01
Positive
44.68
Neutral
23.20
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBBQ, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 29.53, equal to the 50-day MA of 29.16, and equal to the 200-day MA of 26.90, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.68 is Neutral, neither overbought nor oversold. The STOCH value of 23.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBBQ.
IBBQ Peer Comparison
Comparison Results
Performance Comparison
IBBQ
Invesco Nasdaq Biotechnology ETF
28.84
7.94
37.99%
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
XHS
SPDR S&P Health Care Services ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents